[Case Study] Keisuke Kagami and Mitsuru Sugawara “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.” (AMR Alliance Japan, February 22, 2022)
date : 2/22/2022
Tags: AMR
![[Case Study] Keisuke Kagami and Mitsuru Sugawara “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.” (AMR Alliance Japan, February 22, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-case05_ENG-top.jpg)
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital) and Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) reports a case titled “Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
In this study, the usefulness of TDM (Therapeutic Drug Monitoring) for antimicrobial stewardship is reported.
Case study 05
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
![[AMR Case Study 04] Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury](/assets/img/katsudo/icon_pdf_l.png){kind=icon}
Top Research & Recommendations Posts
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
- [Announcement] HGPI Endorses the “Belém Health Action Plan” (November 14, 2025)
- [Publication Report] Planetary Health Promotion Project “Issues Facing Planetary Health and the Role of the Health Sector” (May 10, 2023)
- [Announcement] HGPI Joins Global Green and Healthy Hospitals (August 1, 2023)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Public Comment Submission] “Interim Evaluation of the Implementation Status of the National Biodiversity Strategy 2023-2030 (Draft)” and the “7th National Report under the Convention on Biological Diversity (Draft)” (December 2, 2025)
Featured Posts
-
2025-12-11
[Event Report] Core Components of Universal Health Coverage (UHC): Achieving “Healthcare Without Financial Hardship” in Asia-Pacific and Japan (December 5, 2025)
![[Event Report] Core Components of Universal Health Coverage (UHC): Achieving “Healthcare Without Financial Hardship” in Asia-Pacific and Japan (December 5, 2025)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20251210_Core-Components-of-Universal-Health-CoverageUHC-top.jpg)
-
2025-12-12
[Registration Open] Meaningful Involvement Promotion Project Urgent Symposium “The New Takaichi Administration and Central Social Insurance Medical Council Reform – Ensuring Patients’ Voices are Heard” (January 22, 2026)
![[Registration Open] Meaningful Involvement Promotion Project Urgent Symposium “The New Takaichi Administration and Central Social Insurance Medical Council Reform – Ensuring Patients’ Voices are Heard” (January 22, 2026)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20251208_urgent-symposium-1.png)
-
2025-12-12
[Registration Open] (Webinar) The 140th HGPI Seminar “Early Detection to Reduce COPD Disease Burden: Connecting Clinical Frontiers with Health Policy” (January 27, 2026)
![[Registration Open] (Webinar) The 140th HGPI Seminar “Early Detection to Reduce COPD Disease Burden: Connecting Clinical Frontiers with Health Policy” (January 27, 2026)](https://hgpi.org/en/wp-content/uploads/sites/2/hs140-top.png)
-
2026-01-09
[Registration Open] (Hybrid Format) Dementia Project FY2025 Initiative Concluding Symposium “The Future of Dementia Policy Surrounding Families and Others Who Care for People with Dementia” (March 9, 2026)
![[Registration Open] (Hybrid Format) Dementia Project FY2025 Initiative Concluding Symposium “The Future of Dementia Policy Surrounding Families and Others Who Care for People with Dementia” (March 9, 2026)](https://hgpi.org/en/wp-content/uploads/sites/2/dementia-20260309-top.png)
